Is Aura Biosciences, Inc. (AURA) a Buy, Sell, or Hold?
NASDAQ : AURA
Aura Biosciences, Inc. — Institutional Ownership
$7.04 USD
$0.04 (0.5%)
- Volume
- 422.22K
- Average Volume
- 670.44K
- Market Capitalization
- $451.97M
- P/E Ratio
- -3.98
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $9.54
- Year Low
- $4.73
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.09
Institutional Ownership Summary
Institutional Ownership %
1.45%
Investors Holding
22
change: -105 | last: 127
Increased Positions
11
change: -52 | last: 63
Reduced Positions
6
change: -34 | last: 40
New Positions
1
change: -22 | last: 23
Sold Positions
105
change: 92 | last: 13
Total Calls
-
Total Puts
-
Put-Call Ratio
0.00
change: 0 | last: 0
Total Invested
6.94M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-12 | TCG Crossover GP II, LLC | 4.77M | 5.00% |
| 2026-05-11 | David E. Goel | - | 0.00% |
| 2026-05-11 | Matrix Capital Management Company LP | - | 0.00% |
| 2026-02-17 | Advent Life Sciences LLP | 2.02M | 3.26% |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 4.03M | 6.30% |
| 2025-10-17 | BlackRock, Inc. | 3.34M | 5.40% |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 3.11M | 5.00% |
| 2025-08-13 | Suvretta Capital Management, LLC | 4.7M | 7.60% |
| 2025-07-16 | BlackRock, Inc. | 3.04M | 4.90% |
| 2025-05-23 | Frazier Life Sciences Public Fund, L.P. | 3.86M | 6.10% |
| 2025-05-19 | David E. Goel | 6.92M | 11.17% |
| 2025-05-19 | Matrix Capital Management Company LP | 6.92M | 11.17% |
| 2025-05-15 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 3.32M | 6.60% |
| 2025-05-14 | Eventide Asset Management, LLC | - | 0.00% |
| 2025-05-13 | Eventide Asset Management, LLC | - | 0.00% |
| 2025-04-11 | SUVRETTA CAPITAL MANAGEMENT, LLC | 3.06M | 6.10% |
| 2025-02-14 | Eventide Asset Management, LLC | 4.08M | 8.17% |
| 2025-01-03 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 2.51M | 5.00% |
| 2025-01-03 | LONG FOCUS CAPITAL MANAGEMENT, LLC | 2.51M | 3.60% |
| 2024-11-08 | (1) BlackRock, Inc. | 3.16M | 6.40% |
| 2024-10-22 | (1) BlackRock, Inc. | 3.16M | 6.40% |
| 2023-02-14 | Eventide Asset Management, LLC | 2.25M | 6.30% |
| 2023-02-14 | Robin C. John | 2.25M | 6.30% |
| 2023-02-14 | Finny Kuruvilla, M.D. Ph. D. | 2.25M | 6.30% |
| 2023-02-14 | Finny Kuruvilla, M.D. Ph. D. | 2.25M | 6.30% |
| 2023-02-14 | Robin C. John | 2.25M | 6.30% |
| 2023-02-14 | Eventide Asset Management, LLC | 2.25M | 6.30% |
| 2022-12-15 | Phillip Gross | 2.09M | 5.65% |
| 2022-12-15 | Adage Capital Partners, L.P. | 2.09M | 5.65% |
| 2022-12-15 | Adage Capital Partners GP, L.L.C. | 2.09M | 5.65% |
| 2022-12-15 | Adage Capital Partners, L.P. | 2.09M | 5.65% |
| 2022-12-15 | Adage Capital Partners GP, L.L.C. | 2.09M | 5.65% |
| 2022-12-15 | Adage Capital Advisors, L.L.C. | 2.09M | 5.65% |
| 2022-12-15 | Adage Capital Advisors, L.L.C. | 2.09M | 5.65% |
| 2022-12-15 | Robert Atchinson | 2.09M | 5.65% |
| 2022-12-15 | Robert Atchinson | 2.09M | 5.65% |
| 2022-12-15 | Phillip Gross | 2.09M | 5.65% |
| 2022-02-14 | 2. | 10.0 | 0.00% |
| 2022-02-14 | 2. | 10.0 | 0.00% |
| 2022-02-14 | 2. | 10.0 | 7.90% |
| 2022-02-14 | 2. | 10.0 | 7.90% |
| 2022-02-14 | 2. | 10.0 | 7.90% |
| 2022-02-14 | 2. | 10.0 | 7.90% |
| 2022-02-14 | 2. | 10.0 | 0.00% |
| 2022-02-14 | Advent Life Sciences Fund I LP | 2.02M | 6.90% |
| 2022-02-14 | Advent Life Sciences Fund III LP | 2.02M | 6.90% |
| 2022-02-14 | Advent-Harrington Impact Fund LP | 2.02M | 6.90% |
| 2022-02-14 | Advent Life Sciences Fund III LP | 2.02M | 6.90% |
| 2022-02-14 | ALS III Carry and Co-Invest LP | 2.02M | 6.90% |
| 2022-02-14 | Advent Life Sciences LLP | 2.02M | 6.90% |
| 2022-02-14 | Advent-Harrington Impact Fund LP | 2.02M | 6.90% |
| 2022-02-14 | ALS III Carry and Co-Invest LP | 2.02M | 6.90% |
| 2022-02-14 | Rajesh Parekh, Ph.D. | 2.02M | 6.90% |
| 2022-02-14 | Advent Life Sciences LLP | 2.02M | 6.90% |
| 2022-02-14 | Rajesh Parekh, Ph.D. | 2.02M | 6.90% |
| 2022-02-14 | Advent Life Sciences Fund I LP | 2.02M | 6.90% |
| 2022-02-10 | 2. | 1.6M | 5.48% |
| 2022-02-10 | 2. | 1.6M | 5.48% |
| 2022-01-26 | (“Skole”) | 2.02M | 6.90% |
| 2022-01-26 | Invest A/S (“Lundbeckfond”) | 2.02M | 6.90% |
| 2022-01-26 | Invest A/S (“Lundbeckfond”) | 2.02M | 6.90% |
| 2022-01-26 | (“Skole”) | 2.02M | 6.90% |
| 2021-11-12 | 2. | 10.0 | 12.00% |
| 2021-11-12 | 2. | 10.0 | 12.00% |
| 2021-11-12 | 2. | 10.0 | 12.00% |
| 2021-11-12 | Chiesi Ventures, LP | 1.63M | 5.80% |
| 2021-11-12 | Chiesi Ventures, Inc. | 1.63M | 5.80% |
| 2021-11-12 | Giacomo Chiesi | 1.63M | 5.80% |
| 2021-11-12 | Chiesi Ventures, LP | 1.63M | 5.80% |
| 2021-11-12 | 2. | 10.0 | 12.00% |
| 2021-11-12 | 2. | 10.0 | 8.20% |
| 2021-11-12 | 2. | 10.0 | 8.10% |
| 2021-11-12 | 2. | 10.0 | 8.10% |
| 2021-11-12 | Giacomo Chiesi | 1.63M | 5.80% |
| 2021-11-12 | 2. | 10.0 | 8.10% |
| 2021-11-12 | 2. | 10.0 | 12.00% |
| 2021-11-12 | 2. | 10.0 | 12.00% |
| 2021-11-12 | Chiesi Ventures, Inc. | 1.63M | 5.80% |
| 2021-11-12 | 2. | 10.0 | 8.10% |
| 2021-11-12 | 2. | 10.0 | 8.10% |
| 2021-11-12 | 2. | 10.0 | 8.10% |
| 2021-11-12 | 2. | 10.0 | 8.20% |
| 2021-11-10 | LP | 2.97M | 10.50% |
| 2021-11-10 | Co-Invest | 70540.0 | 0.20% |
| 2021-11-10 | GP Limited | 3.04M | 10.70% |
| 2021-11-10 | Arix Bioscience Holdings Limited | 1.51M | 5.31% |
| 2021-11-10 | Arix Bioscience Plc | 1.51M | 5.31% |
| 2021-11-10 | Arix Bioscience Holdings Limited | 1.51M | 5.31% |
| 2021-11-10 | Co-Invest | 70540.0 | 0.20% |
| 2021-11-10 | Arix Bioscience Plc | 1.51M | 5.31% |
| 2021-11-10 | LP | 2.97M | 10.50% |
| 2021-11-10 | Management (Jersey) Limited | 3.04M | 10.70% |
| 2021-11-10 | GP Limited | 3.04M | 10.70% |
| 2021-11-10 | Management (Jersey) Limited | 3.04M | 10.70% |
| 2021-11-04 | Matrix Capital Management Company LP | 4.11M | 14.48% |
| 2021-11-04 | David E. Goel | 4.11M | 14.48% |
| 2021-11-04 | David E. Goel | 4.11M | 14.48% |
| 2021-11-04 | Matrix Capital Management Company LP | 4.11M | 14.48% |
AURA Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $5.45 | 60.34M | $328.84M | $59.52M | $17.38M | $286.7M |
| 2024-12-31 | $8.22 | 49.65M | $408.13M | $31.69M | $18.77M | $395.2M |
| 2023-12-31 | $8.86 | 39.62M | $351.03M | $41.06M | $19.56M | $329.53M |
| 2022-12-31 | $10.50 | 29.94M | $314.34M | $121.58M | $20.86M | $213.62M |
| 2021-12-31 | $16.98 | 29.21M | $496.01M | $149.06M | $975K | $347.93M |
| 2020-12-31 | $14.80 | 29.22M | $432.45M | $17.39M | $15000 | $415.07M |
| 2019-12-31 | $14.80 | 2.92B | $43.25B | $32.47M | $49000 | $43.21B |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6.69 | 67.45M | $451.22M | $84.79M | $16.99M | $383.42M |
| 2025-12-31 | $5.45 | 60.34M | $328.84M | $59.52M | $17.38M | $286.7M |
| 2025-09-30 | $6.18 | 65.94M | $407.49M | $47.55M | $17.75M | $377.69M |
| 2025-06-30 | $6.26 | 58.02M | $363.18M | $107.37M | $18.11M | $273.92M |
| 2025-03-31 | $5.86 | 50.13M | $293.74M | $38.23M | $18.44M | $273.96M |
| 2024-12-31 | $8.22 | 49.65M | $408.13M | $31.69M | $18.77M | $395.2M |
| 2024-09-30 | $8.91 | 49.66M | $442.5M | $25.41M | $19.08M | $436.18M |
| 2024-06-30 | $7.37 | 49.55M | $365.17M | $30.08M | $19.03M | $354.13M |
| 2024-03-31 | $7.76 | 49.45M | $383.75M | $26.28M | $19.32M | $376.79M |
| 2023-12-31 | $8.86 | 44.44M | $393.71M | $41.06M | $19.56M | $372.2M |
| 2023-09-30 | $8.97 | 38.19M | $342.52M | $55.58M | $20.19M | $307.13M |
| 2023-06-30 | $12.35 | 37.86M | $467.52M | $47.73M | $20.42M | $440.2M |